



# Fluidigm Infectious Disease and Oncology Virtual Summit

July 7, 6:00 am–12:00 pm PT



Date	Time	Track	Presentation Title	Speaker
7-Jul	06:00 - 06:30 AM		Single-cell mapping of human brain cancer reveals tumor-driven education of tumor-associated leukocytes	Burkhard Becher, PhD Professor and Chairman, Institute of Experimental Immunology, University of Zurich
7-Jul	06:30 - 07:00 AM		Deep immunophenotyping of cancer microenvironments by Imaging Mass Cytometry™	Noel de Miranda, PhD Principal Investigator, Leiden University Medical Center
7-Jul	07:30 - 08:00 AM		Deciphering T cell heterogeneity in humans through analysis of antigen-specificity	Evan Newell, PhD Associate Professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
7-Jul	08:00 - 09:00 AM		Development of an extraction-free, saliva-based workflow for SARS-CoV-2 detection with the Biomark™ HD platform	David King, PhD Senior Vice President, Head of R&D Genomics, Standard BioTools Richard Head, MS Director, Genome Technology Access Center, McDonnell Genome Institute, Washington University School of Medicine, St. Louis
7-Jul	09:00 - 09:30 AM		Mass cytometry in vaccine development: utility and considerations	Patrick Reeves, PhD Instructor in Medicine, Massachusetts General Hospital
7-Jul	09:30 - 10:00 AM		Evaluating tumor-immune cell interactions in human lung cancer using multiparametric and spatially resolved tissue analysis	Kurt Schalper, MD, PhD Assistant Professor of Pathology, Director, Translational Immuno-Oncology Laboratory, Yale School of Medicine
7-Jul	10:00 - 10:30 AM		Visualization and Analysis of High-Parameter CyTOF® Data with FCS Express in Record Time	David Novo, PhD President, De Novo Software
7-Jul	10:30 - 11:00 AM		Identification of human immune cell subtypes most vulnerable to IL-1β-induced inflammatory signaling using mass cytometry	Hema Kothari, PhD Assistant Professor, Department of Medicine, Cardiovascular Medicine Division, University of Virginia

7-Jul	11:00 - 11:30 AM		Comprehensive landscape of the tumor microenvironment analyzed with CyTOF® technology	Hiroyoshi Nishikawa, MD, PhD Professor, National Cancer Center, Japan
-------	------------------------	--	---------------------------------------------------------------------------------------	--------------------------------------------------------------------------